As an enzyme inhibitor, Apremilast inhibits phosphodiesterase 4 (PDE4), which in turn decreases the expression of pro-inflammatory cytokines TNF-α and IL-23, shows therapeutic efficacy in psoriasis, psoriatic arthropathies, and Behçet’s syndrome (6). This evidence concerns the gene TNF and psoriasis.